Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I StudyJung Min Lee, Elise C. Kohn, Stanley Lipkowitz et al.|Journal of Clinical Oncology|2017Cited by 241
Mathematical models of breast and ovarian cancersDana‐Adriana Botesteanu, Doron Levy, Stanley Lipkowitz et al.|WIREs Systems Biology and Medicine|2016Cited by 35